NEW YORK (GenomeWeb News) — Shares in Accelr8 were up more than 60 percent this afternoon after the company said the US Patent and Trademark Office gave it a notice of allowance on the first patent related to its diagnostic platform.
Shares in the company were up 1.36 at $3.82 in late-afternoon trading today.
The company said the methods covered by the patent will enable its BACcel system to "quickly identify major multiple-drug-resistant bacteria and their resistance mechanisms."
The patent news comes a day after the Journal of the American Medical Association published a paper stating that methicillin-resistant Staphylococcus aureus infections are more widespread than previously thought, and may kill more US citizens each year than AIDS.